19.74USD-2.03%Mkt Cap: 596.74M USDP/E: —Last update: 2026-05-26
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The compan…
Industry Peers
Diagnostics & Research166.94BUSDP/E 24.7
122.72BUSDP/E 33.6
44.05BUSDP/E 41.1
34.33BCHFP/E 37.8
33.46BUSDP/E 43.3
32.69BUSDP/E 25.5
28.46BUSD—
27.28BUSDP/E 20.3
Indicators:|
Key Statistics
Company
Market Cap596.74M USD
Enterprise Value398.02M USD
Revenue (TTM)339.92M USD
Gross Profit273.20M USD
Net Income (TTM)-24.16M USD
Revenue/Share11.60 USD
Last Price19.74 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees942
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-22.79
PEG—
EV/EBITDA-21.69
EV/Revenue1.17
P/S1.83
P/B1.35
EPS (TTM)-0.42
EPS (Forward)-0.90
52W Range
14.5917% of range44.28
52W High44.28 USD
52W Low14.59 USD
Profitability
Gross Margin79.37%
Oper. Margin-22.00%
EBITDA Margin-5.40%
Profit Margin-7.02%
ROE-5.13%
ROA-4.18%
Growth
Revenue Growth-4.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF64.35M USD
CapEx (TTM)36.02M USD
FCF Margin3.79%
FCF Yield2.16%
Net Debt-224.96M USD
Net Debt/EBITDA12.26
Balance Sheet
Debt/Equity0.08
Current Ratio6.75
Quick Ratio6.26
Book Value/Sh15.23 USD
Cash/Share8.628 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)45.88 USD
Target Range40.00 USD – 52.00 USD
# Analysts8
Ownership
Shares Out.30.33M
Float26.87M
Insiders2.38%
Institutions93.03%
Short Interest
Short Ratio4.8d
Short % Float4.83%
Short % Out.4.71%
Shares Short1.43M
Short (prev mo.)1.53M
Technical
SMA 5023.56 (-16.2%)
SMA 20028.70 (-31.2%)
Beta1.11
S&P 52W Chg28.31%
Avg Vol (30d)431.13K
Avg Vol (10d)518.00K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—